Genomic coordinate (human 10:95,605,401 ALDH18A1) & (mouse 19:40,538,701 Aldh18a1).
Cytoband (human 10q24.1 ALDH18A1) & (mouse 19qC3q Aldh18a1).
Here I present: “Hereditary Spastic Paraplegia”, Victor McKusick, Mendelian Inheritance in Man’, 1966. (ALDH18A1) icd10=G11.4
Hereditary spastic paraplegia (HSP) is a group of progressive genetic disorders characterized by progressive weakness and spasticity (stiffness) in the legs. Caused by mutations affecting nerve axon stability, it results in a “spastic gait” and often requires walking aids. While not typically fatal, it causes chronic mobility issues, with symptoms manageable through physical therapy, medication, and bracing.
Key Aspects of Hereditary Spastic Paraplegia:
Symptoms: Primary symptoms are muscle tightness, weakness in the legs, toe walking, and urinary urgency. Some forms (“complex” or “complicated”) may include vision loss, ataxia, epilepsy, or cognitive impairment.
Causes: HSP is caused by inherited gene mutations (over 80 known types) that lead to neurodegeneration in the spinal cord.
Age of Onset: Symptoms can appear at any age, from early childhood to late adulthood.
Progression and Life Expectancy: It is a progressive disease, but most people with the “pure” form of HSP have a normal life expectancy, although they may eventually require walking aids, such as a cane or wheelchair.
Management: There is no cure. Treatment focuses on managing symptoms with baclofen for spasticity, regular physical therapy for strength, and mobility aids.
Diagnosis: Diagnosis involves reviewing family history, ruling out other conditions like multiple sclerosis, MRI scans, and genetic testing.
Hereditary Spastic Paraplegia (HSP) is extremely genetically heterogeneous.
Today, researchers recognize nearly 100 genetic types (often labeled SPG1, SPG2, SPG3A … up into the 80s–90s range, with new ones still being described).
🧬 What defines a “type”?
Each numbered SPG corresponds to a distinct gene locus.
Example:
SPG4 → SPAST (most common AD form)
SPG3A → ATL1
SPG7 → SPG7
SPG9 → ALDH18A1
Each gene disrupts axonal maintenance in different molecular ways.
🧠 Why so many forms?
The corticospinal tract neurons are:
Extremely long (1 meter axons)
Highly dependent on:
Axonal transport
Mitochondrial dynamics
ER shaping
Lipid metabolism
Cytoskeleton stability
Mutations in many different cellular pathways can produce the same final phenotype:
Progressive lower limb spasticity (length-dependent axonopathy)
So HSP is a final common pathway disorder, not a single disease.
📊 Rough Breakdown
~80–100+ genetic loci identified
Autosomal dominant
Autosomal recessive
X-linked
Rare mitochondrial forms
Clinically divided into:
Pure HSP – mainly spastic paraplegia
Complex HSP – spasticity plus additional features (ataxia, neuropathy, epilepsy, intellectual disability, etc.)
🔬 Conceptual View
Think of HSP as:
“Axon length maintenance failure syndrome”
Different genes → same geometric vulnerability:
long corticospinal axons degenerate first.
If you like numbers:
SPG4 (SPAST) accounts for ~30–40% of AD HSP
The majority of individual SPG types are extremely rare; but, new ones are still being discovered (nearly a hundred is approximant number of HSP disorders).
Autosomal dominant spastic paraplegia-9A (SPG9A) is a neurologic disorder characterized by onset of slowly progressive spasticity mainly affecting the lower limbs. The age at onset usually ranges from adolescence to adulthood, and patients have gait difficulties, motor neuropathy, and dysarthria. Additional variable features include cerebellar signs, cataract, pes cavus, and urinary urgency.
Autosomal recessive SPG9B is a neurologic disorder characterized by early-onset complex spastic paraplegia. Affected individuals had delayed psychomotor development, intellectual disability, and severe motor impairment. More variable features include dysmorphic facial features, tremor, and urinary incontinence.
ALDH and HSP9 (SPG9)
HSP9 / SPG9 is caused by mutations in the gene:
ALDH18A1
Chromosome 10q24.1–q24.2
This gene encodes Δ¹-pyrroline-5-carboxylate synthetase (P5CS) — a mitochondrial enzyme in the aldehyde dehydrogenase (ALDH) superfamily.
🧪 What does ALDH18A1 actually do?
Although classified in the ALDH superfamily, ALDH18A1 is not a detox enzyme like ALDH2.
It is a bifunctional enzyme that catalyzes the first steps of:
Glutamate → Proline / Ornithine pathway
Step 1:
Glutamate + ATP → γ-glutamyl phosphate
Step 2 (ALDH domain step):
γ-glutamyl phosphate → glutamate-5-semialdehyde
→ spontaneously cyclizes to P5C
P5C → Proline (or Ornithine via related pathways)
So the “ALDH” activity here is the glutamate-5-semialdehyde dehydrogenase reaction.
🧠 Why does this cause Hereditary Spastic Paraplegia?
Proline is important for:
Collagen structure
Connective tissue integrity
Redox balance
Mitochondrial function
Axonal maintenance
Corticospinal neurons are extremely long.
They are vulnerable to:
Mitochondrial dysfunction
Redox imbalance
Structural instability
Reduced P5CS activity → impaired proline metabolism → length-dependent axon degeneration → spastic paraplegia.
🔁 Dominant vs Recessive SPG9
Mutations in ALDH18A1 produce:
SPG9A (Autosomal Dominant)
Partial enzyme dysfunction
Later onset, often “pure” HSP
SPG9B (Autosomal Recessive)
Severe loss of function
Earlier onset
Often complex phenotype (developmental delay, cataracts, connective tissue features)
Same gene — different severity thresholds.
🔬 Biochemical Insight
Most ALDH enzymes detoxify aldehydes.
ALDH18A1 instead: Generates a metabolic intermediate (P5C). Links amino acid metabolism to mitochondrial energy balance.
So SPG9 is:
Not aldehyde toxicity. But metabolic insufficiency affecting long motor neurons.
🧭 Conceptual View
ALDH18A1 failure =
“Proline–mitochondria–axon length vulnerability axis.”The corticospinal tract is the geometric weak point.
There is evidence that hereditary spastic paraplegia-9A is caused by mutation in the aldehyde dehydrogenase (ALDH18A1) gene encoded on genomic coordinate 10:95,605,401 and cytoband 10q24.1 in humans.
